Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function

Nature Biotechnology volume 28, pages 486–494 (2010)Cite this article

Subjects

Abstract

The Predictive Safety Testing Consortium's first regulatory submission to qualify kidney safety biomarkers revealed two deficiencies. To address the need for biomarkers that monitor recovery from agent-induced renal damage, we scored changes in the levels of urinary biomarkers in rats during recovery from renal injury induced by exposure to carbapenem A or gentamicin. All biomarkers responded to histologic tubular toxicities to varied degrees and with different kinetics. After a recovery period, all biomarkers returned to levels approaching those observed in uninjured animals. We next addressed the need for a serum biomarker that reflects general kidney function regardless of the exact site of renal injury. Our assay for serum cystatin C is more sensitive and specific than serum creatinine (SCr) or blood urea nitrogen (BUN) in monitoring generalized renal function after exposure of rats to eight nephrotoxicants and two hepatotoxicants. This sensitive serum biomarker will enable testing of renal function in animal studies that do not involve urine collection.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1: For carbapenem A–treated rats, correlation of urinary ELISA and MesoScale Discovery biomarker levels with histomorphologic change.
Figure 2: Correlation of urinary MesoScale Discovery biomarker levels with histomorphologic change for carbapenem A-treated rats.
Figure 3: Correlation of urinary ELISA- and MesoScale Discovery-derived biomarker levels with histomorphologic change in gentamicin-treated rats.
Figure 4: ROC curves for the inclusion and exclusion analysis with eight different nephrotoxicant studies and two different hepatotoxicant studies from Novartis.
Figure 5: Levels of S-cystatin C, BUN and SCr observed in individual animals.
Figure 6: Levels of S-cystatin C, BUN and SCr observed in individual animals.

References

  1. Bonventre, J.V. et al. Next-generation biomarkers for detecting kidney toxicity. Nat. Biotechnol. 28, 436–440 (2010).

    CAS  Article  Google Scholar 

  2. Ferguson, M.A., Vaidya, V.S. & Bonventre, J.V. Biomarkers of nephrotoxic acute kidney injury. Toxicology 245, 182–193 (2008).

    CAS  Article  Google Scholar 

  3. Vaidya, V.S., Ramirez, V., Ichimura, T., Bobadilla, N.A. & Bonventre, J.V. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am. J. Physiol. Renal Physiol. 290, F517–F529 (2006).

    CAS  Article  Google Scholar 

  4. Han, W.K. et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 73, 863–869 (2008).

    CAS  Article  Google Scholar 

  5. Yu, Y., Jin, H., Holder, D., Ozer, J.S. & Villarreal, S. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat. Biotechnol. 28, 470–477 (2010).

    CAS  Article  Google Scholar 

  6. Dieterle, F. et al. Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat. Biotechnol. 28, 463–469 (2010).

    CAS  Article  Google Scholar 

  7. Vaidya, V.S. et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotechnol. 28, 478–485 (2010).

    CAS  Article  Google Scholar 

  8. Mattes, W.B. & Walker, E.G. Translational toxicology and the work of the predictive safety testing consortium. Clin. Pharmacol. Ther. 85, 327–330 (2009).

    CAS  Article  Google Scholar 

  9. Razzaque, M.S. & Taguchi, T. Cellular and molecular events leading to renal tubulointerstitial fibrosis. Med. Electron Microsc. 35, 68–80 (2002).

    CAS  Article  Google Scholar 

  10. Westhuyzen, J. et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol. Dial. Transplant. 18, 543–551 (2003).

    CAS  Article  Google Scholar 

  11. Bailly, V. et al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J. Biol. Chem. 277, 39739–39748 (2002).

    CAS  Article  Google Scholar 

  12. Ichimura, T., Hung, C.C., Yang, S.A., Stevens, J.L. & Bonventre, J.V. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Renal Physiol. 286, F552–F563 (2004).

    CAS  Article  Google Scholar 

  13. Berger, T. et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 103, 1834–1839 (2006).

    CAS  Article  Google Scholar 

  14. Silkensen, J.R., Agarwal, A., Nath, K.A., Manivel, J.C. & Rosenberg, M.E. Temporal induction of clusterin in cisplatin nephrotoxicity. J. Am. Soc. Nephrol. 8, 302–305 (1997).

    CAS  PubMed  Google Scholar 

  15. Orlandi, A. et al. Modulation of clusterin isoforms is associated with all-trans retinoic acid-induced proliferative arrest and apoptosis of intimal smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 25, 348–353 (2005).

    CAS  Article  Google Scholar 

  16. Vaidya, V.S. & Bonventre, J.V. Mechanistic biomarkers for cytotoxic acute kidney injury. Expert Opin. Drug Metab. Toxicol. 2, 697–713 (2006).

    CAS  Article  Google Scholar 

  17. Hoffmann, W. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell. Mol. Life Sci. 62, 2932–2938 (2005).

    CAS  Article  Google Scholar 

  18. Mussap, M. & Plebani, M. Biochemistry and clinical role of human cystatin C. Crit. Rev. Clin. Lab. Sci. 41, 467–550 (2004).

    CAS  Article  Google Scholar 

  19. Takuwa, S., Ito, Y., Ushijima, K. & Uchida, K. Serum cystatin-C values in children by age and their fluctuation during dehydration. Pediatr. Int. 44, 28–31 (2002).

    CAS  Article  Google Scholar 

  20. Madero, M., Sarnak, M.J. & Stevens, L.A. Serum cystatin C as a marker of glomerular filtration rate. Curr. Opin. Nephrol. Hypertens. 15, 610–616 (2006).

    CAS  Article  Google Scholar 

  21. Dharnidharka, V.R., Kwond, C. & Stevens, G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 40, 221–226 (2002).

    CAS  Article  Google Scholar 

  22. Shlipak, M.G., Praught, M.L. & Sarnak, M.J. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr. Opin. Nephrol. Hypertens. 15, 270–275 (2006).

    CAS  Article  Google Scholar 

  23. Herget-Rosenthal, S. et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 66, 1115–1122 (2004).

    CAS  Article  Google Scholar 

  24. Anonymous US Food and Drug Administration Agency 510(k) Substantial equivalence determination decision summary device only. (FDA, Rockville, Maryland, USA, 2007) <http://www.fda.gov/cdrh/reviews/K041878.pdf>.

  25. Sing, T., Sander, O., Beerenwinkel, N. & Lengauer, T. ROCR: visualizing classifier performance in R. Bioinformatics 21, 3940–3941 (2005).

    CAS  Article  Google Scholar 

  26. Hanley, J.A. & McNeil, B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29–36 (1982).

    CAS  Article  Google Scholar 

  27. DeLong, E.R., DeLong, D.M. & Clarke-Pearson, D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845 (1988).

    CAS  Article  Google Scholar 

  28. Rosen, H. et al. Reduced immunotoxicity and preservation of antibacterial activity in a releasable side-chain carbapenem antibiotic. Science 283, 703–706 (1999).

    CAS  Article  Google Scholar 

  29. Sistare, F.D. et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat. Biotechnol. 28, 446–454 (2010).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

S. Leuillet and B. Palate (Centre International de Toxicologie (CIT)) kindly performed Novartis studies and the histopathology assessment and J. Mapes (RBM) developed the S-cystatin C assay. We thank G. Miller and P. Srinivasa for helpful comments on the manuscript. Z.E., K.V. and W.E.G. kindly shared unpublished observations for GST alpha.

Author information

Author notes

  1. Josef S Ozer & Jacky Vonderscher

    Present address: Present addresses: Pharmacokinetics, Dynamics, and Metabolism, PGRD, Pfizer, Andover Laboratories, Andover, Massachusetts, USA (J.S.O.) and Molecular Medicine Labs, Group Research, Hoffmann-La Roche, Basel, Switzerland (J.V.).,

  2. Josef S Ozer and Frank Dieterle: These authors contributed equally to this work.

Affiliations

  1. Department of Investigative Laboratory Sciences, Safety Assessment, Merck Research Laboratories, West Point, Pennsylvania, USA

    Josef S Ozer, Zoltan Erdos, Katerina Vlasakova, Hong Jin, Yan Yu, Tom Forest, Spencer Reynolds, Wendy J Bailey, Douglas T Thudium, Michael J Topper, Thomas R Skopek, Joseph F Sina, Warren E Glaab, Frank D Sistare & David L Gerhold

  2. Translational Sciences, Novartis Institutes for BioMedical Research, Novartis, Basel, Switzerland.

    Frank Dieterle, Elias Perentes, André Cordier, Pablo Verdes, Frank Staedtler, Andreas Mahl, Olivier Grenet, Daniel R Roth, Daniel Wahl, François Legay, Jacky Vonderscher, Gérard Maurer & Salah-Dine Chibout

  3. Department of Pathology, Safety Assessment, Merck Research Laboratories, West Point, Pennsylvania, USA

    Sean Troth & Nagaraja Muniappa

  4. Department of Biometrics, Merck Research Laboratories, West Point, Pennsylvania, USA

    Daniel Holder

  5. Department of Exploratory Toxicology, Safety Assessment, Merck Research Laboratories, West Point, Pennsylvania, USA

    Holly K Clouse

Authors
  1. Josef S Ozer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Dieterle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sean Troth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elias Perentes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. André Cordier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pablo Verdes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Frank Staedtler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andreas Mahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Olivier Grenet
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daniel R Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Daniel Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. François Legay
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Daniel Holder
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Zoltan Erdos
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Katerina Vlasakova
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hong Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Yan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Nagaraja Muniappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Tom Forest
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Holly K Clouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Spencer Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Wendy J Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Douglas T Thudium
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Michael J Topper
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Thomas R Skopek
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Joseph F Sina
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Warren E Glaab
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Jacky Vonderscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Gérard Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Salah-Dine Chibout
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Frank D Sistare
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. David L Gerhold
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.S.O., F.D., W.J.B., M.J.T., T.R.S., J.F.S., W.E.G., E.P., A.C., F.S., A.M., O.G., D.R.R., F.L., S.-D.C., G.M., J.V., D.L.G., F.D.S. and D.W. designed research; Z.E., T.F., N.M., E.P., D.R.R., S.T., H.K.C., S.R., D.T.T., K.V. and H.J. performed research; Z.E. and K.V. contributed new reagents/analytic tools; J.S.O., D.H., N.M., W.E.G., F.D., Y.Y., G.M., P.V., A.C., D.L.G. and F.D.S. analyzed data; and J.S.O., S.T., Z.E., K.V., F.D., D.L.G. and F.D.S. wrote the paper.

Corresponding author

Correspondence to David L Gerhold.

Ethics declarations

Competing interests

All authors are present or past employees of Merck or Novartis.

Supplementary information

Supplementary Text and Figures

Supplementary Tables 1,2 and Supplementary Figs. 1–4 (PDF 655 kb)

Supplementary Data Set (XLS 315 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ozer, J., Dieterle, F., Troth, S. et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 28, 486–494 (2010). https://doi.org/10.1038/nbt.1627

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1627

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing